From early stage discovery to clinical trials and approval, we’re Taking Cancer On. Click here to access the podcast homepage, where you will find all the available episodes.
By using creativity and persistence, the packaging department team at Yamagata, Japan, managed to reduce their waste plastic material by 11 per cent, making them an inspiration for all sites globally.
Non-small cell lung cancer (NSCLC) is the most common form of lung cancer, accounting for 80-85% of all lung cancer cases. Find out more about testing and treatment here.
Targeting MDM2-p53 in cancer: The story of Brigimadlin
Our perseverance and passion for science led to the discovery of Brigimadlin, our MDM2-p53 antagonist, that is being clinically investigated as a potential treatment for dedifferentiated liposarcoma, a rare cancer with significant unmet needs.
T-cell engagers: Reawakening T-cells to fight cancer
Lamine Mbow, our Global Head of Cancer Immunology and Immune Modulation, shares our approach to immuno-oncology, highlighting our T-cell engagers platform and how we are driving innovation to deliver meaningful advances to people with cancer.